On April 10, 2018, the Food and Drug Administration (FDA) approved everolimus tablets for oral suspension (brand name: Afinitor Dispersz, Novartis Pharmaceuticals Corporation) as an adjunctive therapy to treat partial-onset refractory seizures in adults and children over 2 years of age with Tuberous Sclerosis Complex (TSC). Tuberous Sclerois isa genetic disorder that affects one million people worldwide and is characterized by benign tumors in several organs, epilepsy, behavioral problems and intellectual disability.

A recent study published in the New England Journal of Medicine (NEJM) shows a purified cannabidiol (CBD) medication called Epidiolex may help to curb seizures in children and young adults with Dravet syndrome. Read More

The Foundation for Angelamn Syndrome Therapeutics (FAST) launches a new biotech, GeneTx Biotherapeutics LLC (GeneTx), a subsidiary of FAST, for the development and commercialization of an investigational antisense drug, GTX-101, for the treatment of Angelman syndrome (AS), a rare genetic disorder characterized by epilepsy, impaired motor function and speech delays. Read More

Dr. Anne Anderson, epileptologist at Texas Children's Hospital and investigator at the Cain Labs and Jan and Dan Duncan Neurological Research Institute. Read the blog posted on the Foundation for Angelman Syndrome Therapeutics website that describes Dr. Anderson's latest research findings on Angelman syndrome.

A study published in Scientific Reports from the laboratory of Dr.

David Cameron’s son Ivan was born with a neurological disorder that baffled doctors. He was later diagnosed with a rare epileptic syndrome, Ohtahara syndrome. Now, he writes, genomic testing can end the anguish of uncertainty.

Read More

On International Epilepsy Day (Feb 12th), Texas Children's experts, an epileptologist, Dr. Dave Clarke, Ms. Jillian Davis, lead dietitician for ketogenic diet program and Dr. Rebecca Schultz, pediatric nurse practiitioner, share valuable information about the benefits of ketogenic diet for epilepsy patients.

What is epilepsy, and who is affected?

A study shows that structural alterations in neurons and the resulting memory deficits that arise after a single generalized seizure can be reversed by inhibiting the Phosphoinositide 3-kinase/Akt kinase/mechanistic target of rapamycin (i.e. PI3K/Akt/mTOR) signaling pathway.